Keryx Biopharmaceuticals, Inc. was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $6.5–$7.8 in the past one-month time frame, witnessed a sharp increase on Friday.

The company has seen no estimate revisions over the past one month, and the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future. 

Keryx Biopharmaceuticals currently has a Zacks Rank #4 (Sell) while its Earnings ESP is negative.

Keryx Biopharmaceuticals, Inc. Price and Consensus

Keryx Biopharmaceuticals, Inc. Price and Consensus | Keryx Biopharmaceuticals, Inc. Quote

A better ranked stock in the Medical - Biomedical and Genetics industry is Alexion Pharmaceuticals, Inc. which carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is KERX going up? Or down? Predict to see what others think: Up or Down

New Report: An Investor’s Guide to Cybersecurity

Cyberattacks have become more frequent and destructive than ever. In fact, they’re expected to cause $6 trillion per year in damage by 2020.

The cybersecurity industry is expanding quickly in response to these threats. In fact, a projected $170 billion per year will be spent to protect consumer and corporate assets. Zacks has just released Cybersecurity: An Investor’s Guide to Locking Down Profits which reveals 4 promising investment candidates.

Download the new report now>>